Unassociated Document
UNITED
STATES SECURITIES AND
EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): November
30, 2006
GAMMACAN
INTERNATIONAL, INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State
or
other jurisdiction of incorporation)
0-32835
(Commission
File Number)
33-0956433
(IRS
Employer Identification No.)
39
Jerusalem St., Kiryat Ono 55423 Israel
(Address
of principal executive offices and Zip Code)
Registrant's
telephone number, including area code: 972
3 738 2616
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-2-
ITEM
7.01 Regulation
FD Disclosure
On
November 30, 2006, GammaCan International, Inc. made a presentation concerning
its results regarding the efficacy and safety of IVIG intravenous immunoglobulin
in patients with metastatic melanoma at the 5th
International Congress of Autoimmunity in Sorrento, Italy. The materials
utilized during the presentation are filed as Exhibit 99.1 to, and incorporated
by reference in, this report. In accordance with Regulation FD, this current
report is being filed to publicly disclose all information that was provided
in
its press release. This report under Item 7.01 is not deemed an admission as
to
the materiality of any information in this report that is required to be
disclosed solely by Regulation FD.
ITEM
9.01. Financial Statements and Exhibits.
(c) Exhibits.
| 99.1 |
Presentation
Materials.
|
-3-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
GAMMACAN
INTERNATIONAL, INC.
|
| |
|
| |
/s/
Patrick Schnegelsberg
|
| |
Patrick
Schnegelsberg,
|
| |
Chief
Executive Officer
|
| |
|
| |
Date:
December 12, 2006
|